IND submission is a major milestone in the life of your drug. We can provide all supporting analytical data to help ensure a smooth application process.
We have the expertise, flexibility, and resources to provide a full range of pharmaceutical API custom development services at every stage of the lifecycle.
We can provide lab-, kilo- and pilot-scale manufacturing for preclinical studies and all phases of clinical trials, supplying milligram to kilogram quantities.
Cambrex brings more than 40 years of generic API manufacturing experience to its pharmaceutical partners. From our sites in Italy, Sweden, and the USA, we are a leading global supplier of generic APIs.
Drug substance tech transfer sounds so simple on the surface, but it’s a complex activity carrying a number of technical, regulatory, and quality risks.
At Snapdragon Chemistry, now part of Cambrex, our chemists specialize in creating custom solutions and technologies to take on your toughest process development and production challenges. This includes expertise in designing and building reactors that enable seamless technology transfer as a process scales up for commercial manufacturing.
At Cambrex, we provide a range of technologies equipped to solve your API manufacturing challenges, and we are flexible enough to handle the most complex molecules.
You can rely on our extensive portfolio of analytical development solutions and testing services to rapidly advance your molecule for the greatest chance of success.
We’re solid state chemistry experts who can deliver timely, phase-appropriate solutions to optimize the physical stability of your API, develop a more bioavailable formulation or overcome other challenges.
Cambrex’s experienced analysts are well-equipped to ensure microbial testing is of the highest quality for our customers and delivered with a quick and reliable turnaround.
Cambrex and Q1 Scientific’s stability storage and sample management capabilities provide a variety of pharmaceutical storage conditions, with walk-in and reach-in chambers that meet all ICH Q1A requirements.
Cambrex offers extensive development services tailored to meet your drug product needs in early development. From pre-formulation to Phase II, we ensure your products are developed with speed, flexibility, and quality in mind.
Whether you need rapid development, flexible manufacturing solutions, or high-quality production, Cambrex is your trusted partner for advancing your drug product from concept to the clinic.
Cambrex is here to support you in early-phase development. Our development experts apply their ingenuity and skill to address your unique challenges.
Our teams of creative problem-solvers work closely with you to accelerate drug development timelines, optimize processes, and meet regulatory requirements.
We understand that the commercial phase of drug development can be challenging, especially when it comes to manufacturing at scale and meeting changing market demands.
Cambrex is a leading global supplier of more than 70 generic APIs, as well as intermediates and derivatives.
Recent growth in the number of HPAPIs in development has created increased demand for capacity at CDMOs. To address this, Cambrex has been working for expand its HPAPI capabilities to better serve clients, starting with a new high potency laboratory in our Milan site to support process and analytical development and manufacturing. In our recent article in Specialty Chemicals Magazine, Cambrex’s Daniele Vigo and Matthew Bio share a case study on the approach used for the design and qualification of our isolators and the development of the highly potent generic API, olaparib, from the newly commissioned facility. The key highlights of the article include:
Read the entire article, “HPAPIs: From Niche Capability to Core Competency,” to learn more about our approach and the results.
View the full article (via Specialty Chemicals Magazine)
In our recent Organic Process Research & Development article, we discuss our collaboration with Pfizer, focusing on efforts to translate an early-stage batch route for the AXL-MER inhibitor oncology candidate PF-07265807 into a viable continuous flow process.
In our recent Organic Process Research & Development article, we discuss our collaboration with Alexion Pharmaceuticals on the technology transfer and process development of danicopan, an orally administered complement Factor D (FD) inhibitor, focusing on the challenges faced and strategies employed to meet client expectations within a compressed timeline.
In this article, we describe our team’s approach to the development of an improved synthesis of the pharmaceutically relevant building block 2-butylbenzofuran (BBF) by utilizing a telescoped hybrid batch–flow process composed of three steps.